- Home
- ZNTL vs RMM Comparison
ZNTL vs RMM Comparison
Compare ZNTL & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- RMM
- Stock Information
- Founded
- ZNTL 2014
- RMM 2019
- Country
- ZNTL United States
- RMM United States
- Employees
- ZNTL N/A
- RMM N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- RMM Trusts Except Educational Religious and Charitable
- Sector
- ZNTL Health Care
- RMM Finance
- Exchange
- ZNTL Nasdaq
- RMM Nasdaq
- Market Cap
- ZNTL 238.2M
- RMM 309.7M
- IPO Year
- ZNTL 2020
- RMM N/A
- Fundamental
- Price
- ZNTL $3.12
- RMM $15.91
- Analyst Decision
- ZNTL Buy
- RMM
- Analyst Count
- ZNTL 7
- RMM 0
- Target Price
- ZNTL $10.86
- RMM N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- RMM 66.5K
- Earning Date
- ZNTL 11-04-2024
- RMM 01-01-0001
- Dividend Yield
- ZNTL N/A
- RMM 7.33%
- EPS Growth
- ZNTL N/A
- RMM N/A
- EPS
- ZNTL N/A
- RMM 0.96
- Revenue
- ZNTL $40,560,000.00
- RMM N/A
- Revenue This Year
- ZNTL N/A
- RMM N/A
- Revenue Next Year
- ZNTL N/A
- RMM N/A
- P/E Ratio
- ZNTL N/A
- RMM $15.55
- Revenue Growth
- ZNTL N/A
- RMM N/A
- 52 Week Low
- ZNTL $2.83
- RMM $12.32
- 52 Week High
- ZNTL $18.24
- RMM $16.10
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- RMM 50.91
- Support Level
- ZNTL $2.92
- RMM $15.70
- Resistance Level
- ZNTL $3.23
- RMM $16.07
- Average True Range (ATR)
- ZNTL 0.17
- RMM 0.20
- MACD
- ZNTL 0.00
- RMM -0.02
- Stochastic Oscillator
- ZNTL 38.33
- RMM 31.34
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.